(Circulation. 2000;102:IV-58.)
© 2000 American Heart Association, Inc.
Special Anniversary Issue |
Pediatric Cardiology and Cardiovascular Surgery: 1950–2000
From the Division of Cardiology, Department of Pediatrics, the Hospital for Sick Children and University of Toronto Faculty of Medicine (R.M.F.); the Department of Cardiology, the Children’s Hospital and Harvard Medical School, Boston (J.L.); and the Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Tex (J.T.B.).
Correspondence to Robert M. Freedom, MD, The Hospital for Sick Children, 555 University Ave, Room 1503, Toronto, Ontario, Canada M5G 1X8. E-mail rfreedom{at}sickkids.on.ca
Key Words: defects • Fontan procedure • pediatrics • prostaglandins • transposition of great vessels
For those caring for the patient with congenital heart disease, the last 50 years of the 20th century was witness to staggering advances in virtually all aspects of pediatric cardiovascular medicine and surgery. The first half of the 20th century was not dormant in this regard. Dr Maude Abbott of Montreal had published her wonderful atlas in 1936 under the auspices of the American Heart Association, a unique compilation of 1000 cases of congenital heart disease.1 Dr Helen Taussig of Baltimore had founded her cardiac clinic at Johns Hopkins and had begun in the 1930s to characterize the clinical and fluoroscopic findings of a wide variety of congenital heart malformations; this material matured into her 2-volume compendium on congenital heart disease published in 1960.2 Dr Robert E. Gross of the Children’s Hospital in Boston successfully ligated the patent arterial duct in 1938, and that signal accomplishment ushered in the era of surgery for congenital heart disease.3 On the basis of her clinical observations that some children with cyanotic congenital heart disease became progressively more cyanotic coincidently with closure of the arterial duct and cognizant of Gross’s benchmark contribution, Dr Taussig traveled to Boston to attempt to persuade him to construct an arterial duct. When he refused, she broached the subject to Dr Blalock at Johns Hopkins. Some years earlier, when in Vanderbilt and with the technical assistance of Vivien Thomas, in an attempt to produce pulmonary hypertension and using the dog as the experimental animal, Dr Blalock constructed an end-to-end surgical anastomosis between the subclavian artery and the pulmonary artery. With Dr Alfred Blalock as the surgeon and the wisdom of his assistant Vivien Thomas, Taussig and Blalock revolutionized the care of the cyanotic child with the construction of the subclavian artery–to–pulmonary artery end-to-side anastomosis, thus augmenting pulmonary blood flow, and published their early experience in 1945.4 Coarctation of the aorta was successfully repaired in 1945 by Crafoord and Nylin of Stockholm5 ; Brock, using a "closed" technique, performed a pulmonary valvotomy6 ; and in 1950, Blalock and Hanlon performed an atrial septectomy using the surgical clamp designed by Vivien Thomas.7 And then came the last half of the 20th century.
Perinatal Cardiac Physiology
An understanding of the physiology of the unique aspects of the circulation of the fetus and neonate, as well as the concept of the transitional circulation, had a profound impact on the development of treatment modalities in pediatric cardiology.8 9 10 Basic understanding of developmental cardiovascular physiology allowed a number of medical and surgical advances in the care of infants with heart disease. Research regarding the distribution of blood flow in the fetus and the changes in flow and in vascular channels at the time of birth led to the concept of the persistent fetal circulation (or persistent transitional circulation). These babies were often mistaken for babies with significant structural cardiac malformations, and attempts at definitive diagnosis or intervention could be disastrous. The relative contribution of changes in stroke volume and heart rate in the potential for providing cardiac output reserve of the neonate compared with the adult led to insights of profound importance in neonatal cardiac care. Research that led to an understanding of myocardial perfusion in the developing heart and the unique metabolic aspects of the neonatal heart opened the way for efficient cardioplegia and myocardial protection, pharmacological circulatory support, and neonatal cardiac resuscitation.
Rudolph and his colleagues, among many others, have fully characterized the fetal circulation, demonstrating flow patterns of the great veins; the fetal channels, including the ductus venosus and the arterial duct; and the obligatory right-to-left shunting at the level of the foramen ovale occurring in the fetus.8 9 10 The nature of the combined ventricular output in the fetal lamb has been determined, and the relative distributions of flow to the collapsed and unaerated lungs, as well as to the various components of the aortic arch, the transverse aortic arch, and the isthmus. Those complex overlapping changes responsible for the normal functional and anatomic closure of the arterial duct have also been elucidated. In part, the understanding of the pharmacological and physiological manipulation of the arterial duct led to the development of prostanoid therapy and to biological manipulation of the arterial duct. Many have shown that the contractility or force generated by fetal myocardium is less than that generated by adult myocardium. There is evidence that many of the subcellular elements of the contractile response in the fetus are relatively immature and that a substantial increase in ß-adrenergic receptor concentration takes place after birth. The factors responsible for the increase in ß-adrenergic receptor concentration are not completely understood, but certainly thyroid hormone has a substantial role. The role of afterload in the fetal heart and the response of global ventricular function to a changing heart rate have also been studied in detail. Many have been interested in these perinatal changes, especially as they manifest themselves in so-called disturbances of the transitional circulation, including persistent fetal circulation or transitional myocardial ischemia of the newborn, the latter a phenomenon fully characterized by the late Richard Rowe. The central fetal circulation changes dramatically at birth. The inefficient separation of the oxygen uptake and delivery circulations of the fetus is replaced by 2 distinct circulations in series after birth. This parallel circulation is achieved by closure of the arterial duct and the ductus venosus, the separation of and from the umbilical circulation, and the cessation of the right-to-left flow or shunting through the foramen ovale. Coincident with these changes is a substantial increase in pulmonary blood flow and an increase in output from each ventricle. Clearly, ventilation, oxygenation, and umbilical cord occlusion are the gross events responsible for the transition from the fetal circulatory pattern to the circulatory pattern of the newborn. These phenomena are mediated by a complex tapestry of neurohumoral, mechanical, and environmental factors. The structure and function of the arterial duct and its physiological and pharmacological manipulation led both to the development of indomethacin therapy to promote functional and anatomic closure and to prostanoid therapy to maintain ductal patency. The biological mechanisms responsible for duct closure have led to its novel biological manipulation (see below).
Cardiac Anatomy and the Nosology of Congenital Heart Disease
The contributions of Drs Maurice Lev of the Hektoen Institute; Jesse Edwards of the Mayo Clinic and the Charles T. Miller Hospital; Richard Van Praagh of Toronto, Chicago, and then Boston; Robert H. Anderson of London; and Anton Becker of Amsterdam, among others, must be singled out as critically important to the foundation of congenital heart disease: the study of congenitally malformed hearts.11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 With their clinical colleagues, they compiled clinicopathological correlations and published extensively on specimens that constituted their cardiac registries. Collectively, they described and characterized the entire spectrum of congenitally malformed hearts and produced a number of classifications of various cardiac anomalies, including tricuspid atresia, interruption of the aortic arch, truncus arteriosus, ventricular septal defect, double-inlet ventricle, and double-outlet right ventricle.
Although all of the cardiac morphologists mentioned above and their respective colleagues concentrated on descriptive anatomy and definition of unifying morphological features, Lev, Anderson, and Becker also provided detailed information about the specialized conduction tissue in the normal and malformed heart, with special emphasis on the conduction system of hearts with congenitally corrected transposition of the great arteries and "single"-ventricle malformations.
One of the many conundrums facing those caring for patients with congenital heart disease was the issue of classification and thus communication. In an attempt to wrest clarity from chaos, Richard Van Praagh and his colleagues, in a series of important articles beginning in the early 1960s from Toronto and then from Boston, provided the framework for the segmental analysis of congenital heart disease.11 12 13 14 15 16 17 Three segments were identified: the atria, the ventricular loop (d or l), and the great arteries. By use of deductive morphology, the various segments could be connected. Van Praagh and his colleagues emphasized in their many publications the conal or infundibular anatomy of the hearts under discussion, fully characterizing the conal anatomy of normal hearts, hearts with tetralogy of Fallot, truncus arteriosus, complete and corrected transposition of the great arteries, isolated ventricular inversion, anatomically corrected malposition of the great arteries, etc. Eschewing a "deductive" approach to segmental analysis, Dr Robert Anderson and his colleagues from the United Kingdom, using a segmental approach, advocated a sequential "connections" approach.22 23 24 This approach did not focus on infundibular anatomy, and their initial approach did not use the concept of ventricular loops, nor did their approach incorporate the bracketed shortcut alphabet nomenclature. These 2 schools of cardiac nomenclature were initially quite polarized, and although they share many similarities, their differences have not been completely resolved. Thus, these 2 schools of cardiac nomenclature are now widely used by the loyal disciples of each. As yet, the "Esperanto" of congenital heart disease has not been fully realized, although many use an amalgam of the 2 schools.27
Cardiac Catheterization and the Calculation of Pulmonary Vascular Resistance
Right heart catheterization, first performed in the late 1940s, matured in the 1950s to left heart catheter investigations, with the left heart entered through preexisting defects in the atrial or ventricular septum or from the retrograde arterial approach.29 30 31 32 The determination or measurement of oxygen saturation in the various heart chambers allowed for calculation of left-to-right shunt, right-to-left shunt, and effective pulmonary blood flow. The application of the Fick principle permitted calculation of the pulmonary vascular resistance. The calculated pulmonary vascular resistance could be correlated with clinical features and outcome of surgery or no surgical intervention. The correlation of calculated pulmonary vascular resistance with the histological determination of pulmonary vascular disease also provided important information.
An understanding that pulmonary vascular resistance helps determine pulmonary blood flow in patients with congenital cardiac malformations.33 34 35 36 In 1950, it was not understood which patients with large ventricular septal defects would survive surgery and when the elevated pulmonary artery pressure would come down after ventricular septal defect closure. The concept of high pulmonary pressure from high flow in some patients and high resistance was hardly intuitive. Calculation of pulmonary vascular resistance led to an understanding of pulmonary vascular obstructive disease, to better patient selection for heart surgery, and to optimal timing of operative intervention. Ultimately, this also led to pharmacological interventions for elevated pulmonary vascular resistance.
Diagnosis of Congenital Heart Disease
Cardiac catheterization became a reality in the 1940s, and right heart and then left heart cardiac catheterization became a reality for infants and children in the 1940s and 1950s.36 37 38 39 40 41 42 43 44 45 46 47 48 Single fixed-plane angiographic equipment evolved to biplane equipment, and by the 1970s, at least one plane was movable.32 37 45 48 Cut-film technique evolved to cineangiograms, from 16 mm to 35 mm. Bargeron and his colleagues and others, beginning in the mid 1970s, introduced axial angiocardiography, and these angled views were rapidly assimilated.39 40 41 42 43 44 45 Wonderful images were achieved with large-bore catheters and "adequate" amounts of contrast delivered rapidly by pressure injectors. From cine technique, now studies are archived on CDs, and many facilities store and archive in a "cineless" environment. M-mode echocardiography of the 1970s gave way to cross-sectional imaging in the early 1980s. Sahn, Silverman, Williams, Huhta, Smallhorn, and others catalogued the diagnostic features of the entire spectrum of congenital heart malformations.49 50 51 52 53 Color Doppler technology added yet another dimension to this noninvasive imaging modality. In many centers, cross-sectional echocardiography replaced cardiac catheterization and angiocardiography as the primary diagnostic tool, and cardiac operations were planned and executed on the basis of echocardiography. Thus, imaging algorithms for the patient with congenital heart disease, as in the patient with acquired heart diseases, continue to evolve, with more and more information gleaned noninvasively. The transesophageal approach to cross-sectional echocardiography has now been extended to very small infants, with some probes used in infants of 2 to 3 kg, and this intraoperative approach has dramatically reduced the need for immediate postoperative reoperation. Contrast echocardiography, cardiac CT, MRI, single photon emission CT perfusion imaging, stress echocardiography, tissue Doppler characterization, 3D echocardiography, PET, and intravascular ultrasound are but some of the newer imaging tools.54 With these modalities, used in isolation or in combination, considerable information about cardiac structure, function, myocardial perfusion, and tissue characterization can be obtained. Fetal echocardiography has provided a new frontier for diagnosis, counseling, and treatment. Certainly the last 15 years of the 20th century can be seen as the apogee of cross-sectional echocardiographic imaging. From the 1950s onward, large textbooks devoted to the practice of pediatric cardiology and its subspecialty areas were published.
The Prostaglandin Story
Clinical trials to manipulate the patency of the ductus arteriosus with pharmacological agents arose directly from the basic research in cardiovascular development.55 56 57 58 59 60 61 62 63 64 65 Maintaining patency of the ductus arteriosus with prostaglandin E1 has profoundly changed the potential for intervention for babies with many serious structural heart malformations. This treatment option potentially impacts the care of neonates with critical left-sided obstructive lesions and with transposition physiology as well as that of cyanotic newborns whose only source of pulmonary blood is the ductus arteriosus. The impact has been to lower mortality and allow planned operations to replace desperate and frantic attempts at emergency palliations. Preoperative evaluation has become more thorough and safer because of this treatment. Pharmacological ductal closure in the premature with indomethacin provided an option to avoid high-risk cardiovascular operations in this group of babies.
The "bench-to-bedside" paradigm of prostanoid therapy is a wonderful story that is founded in the physiology of the arterial duct. The role of the arterial duct in the "normal" circulation of the fetus and in the transitional circulation was unraveled by Abraham Rudolph and his colleagues and many others.62 They clearly defined those physiological parameters to which the arterial duct responded and helped to clarify pharmacological manipulations that could lead to ductal constriction and closure or to persistent patency. Coceani and Olley, among others, demonstrated in the lamb model that patency of the arterial duct could be maintained through administration of an E-type prostaglandin.55 56 57 From the laboratory animal, an E-type prostaglandin was initially used in the patient with duct-dependent pulmonary blood flow, and then the indications were rapidly extended to the patient with duct-dependent systemic blood flow, including neonates with hypoplastic left heart syndrome, coarctation of the aorta, interruption of the aortic arch, and neonatal critical aortic stenosis. It was clinically evident that ductal patency in the neonate with complete transposition of the great arteries was an advantage, and thus prostanoid therapy was offered to this group of patients as well. By the mid to late 1970s, prostaglandin therapy was firmly entrenched in the therapeutic algorithm of a wide range of patients. Not unexpectedly, a host of potential complications associated with prolonged administration of prostaglandin therapy emerged as well.58 66 67 68 69 70 71 72 73 The functional and physiological manipulation of the arterial duct of the last quarter of the 20th century will soon be history. Functional and anatomic closure of the arterial duct requires prenatal formation of intimal cushions. Their formation requires fibronectin-dependent smooth muscle migration. Mason and her colleagues from the laboratory of Dr Marlene Rabinovitch in Toronto have shown that in the fetal lamb, if the fibronectin mRNA binding protein was sequestered, fibronectin translation was inhibited and intimal cushion formation prevented, thus promoting persistent patency of the arterial duct.74 Thus, in slightly more than 60 years, we have witnessed the following accomplishments: surgical closure of the arterial duct, construction of an arterial duct (the Blalock-Taussig shunt), unraveling the physiology of the arterial duct and its pharmacological manipulation, the prostaglandin story, catheter closure of the arterial duct, and biological manipulation of the arterial duct.
Catheter-Based Therapy in Congenital Heart Disease
Rubio-Alvarez et al, in 1953, described the technique
by which pulmonic stenosis could be relieved by a catheter
technique.75 A
quarter of a century later, Semb et al, using an inflated
balloon-tipped angiographic catheter, ruptured the valve when the
catheter was withdrawn from the main pulmonary artery to the
right ventricle, reducing the outflow
gradient.76 However,
it was the introduction of static balloon dilation by Kan and her
colleagues that fostered the application of this therapeutic modality
to a greater
audience.77 78
Over the past 2 decades, the technique has become the "treatment of
choice" for pulmonary valve stenosis at any age and with any valve
morphology. The safety and efficacy of the technique in infants,
children, and adolescents has been confirmed by numerous studies
summarized by McCrindle and
Kan.78 But
catheter-based therapy for congenital heart disease was clearly focused
by the then novel approach of Rashkind and Miller, who in 1966
demonstrated the role of balloon atrial septostomy as a maneuver to
promote mixing at the atrial level in the patient with complete
transposition of the great
arteries.79 The
application of this technique forever changed the outcome for patients
with transposition of the great arteries and was immediately
assimilated into the therapy of the neonate with transposition and
inadequate mixing. Soon, the approach was extended to patients with
obligatory right-to-left shunting at the atrial level and to those with
obligatory left-to-right shunting at the atrial level, where atrial
restriction was clinically important. Porstmann et al first advocated a
percutaneous technique for permanent closure of the arterial duct,
which could be achieved via the femoral artery, in the late 1960s, but
this technique was not widely
used.80 81
Closure was accomplished with an Ivalon (polyvinyl alcohol) plug
introduced by catheterization from the femoral artery. The 1980s were
witness to a virtual explosion of catheter-based therapy. Balloon
dilatation was offered to patients with aortic stenosis, valvar and
subvalvar; native and recoarctation of the aorta; pulmonary
arterial stenosis, acquired and congenital; and to a wide range of
acquired obstructions (Mustard or Senning baffles, etc). Catheter
closure of the arterial duct with any of a variety of
catheter-delivered devices or coils became standard practice, as did
closure of the atrial septal defect or foramen ovale. In the late 1980s
and throughout the 1990s, there was increasing experience with catheter
closure of the muscular ventricular septal defect. Lock in Boston,
Mullins in Texas, Tynan and Quereshi in London, Benson in Toronto,
and their respective colleagues pioneered many of these applications,
but certainly the Boston and Houston groups paved "the yellow brick
road." Today, fistulae in the coronary, systemic, and pulmonary
circulations are often addressed primarily with catheter-based therapy.
Other applications of these techniques include dilatation of the
pulmonary outflow tract in tetralogy of Fallot and wire or
radiofrequency perforation of the pulmonary valve in pulmonary atresia
and intact ventricular septum or in the patient with membranous
pulmonary atresia and ventricular septal defect. It was soon
appreciated that static balloon dilatation of acquired pulmonary
arterial stenosis all too frequently did not produce sustained
improvement. The introduction of endovascular stents into the stenotic
and hypoplastic pulmonary artery afforded considerable improvement for
many patients, and stents have now been implanted in stenotic conduits
as a maneuver to delay conduit replacement. Such endovascular stents
have now been applied to some patients with native and acquired
recoarctation of the aorta, and patients with diffuse aortitis from
Takayasu’s arteritis have benefited from this therapy. Endovascular
stents have been used in some patients with focal hypoplasia of the
transverse aortic arch, thus obviating the need for surgery. Stents
have been used in the arterial duct, the atrial septum, and pulmonary
veins with variable success. Today, there are relatively few areas of
the cardiovascular system that have not been explored by the
interventional pediatric cardiologist. Stents can be used to
rehabilitate obstructed femoral and iliac veins and acquired inferior
caval obstruction. One can use stents to widen narrowed baffle channels
after Mustard’s or Senning’s procedures and to improve constricted
circuits within a lateral tunnel or extracardiac Fontan. Devices can be
used to occlude acquired systemic venous–to–pulmonary venous channels
after the Fontan or bidirectional cavopulmonary shunt or to occlude
systemic venous–to–systemic venous connections after a bidirectional
cavopulmonary shunt, such channels reducing the effective pulmonary
blood flow. Devices can be used to occlude important aortopulmonary
collaterals before any form of intraoperative repair, but especially
before Fontan-type surgery. Endovascular stents can be used to widen
stenotic aortopulmonary collaterals to palliate some patients with
complex pulmonary atresia. The applications and literature have been
amply reviewed in books published by Lock et al in 1987 and Rao in
1993.82 83
The treatment of a wide variety of tachyarrhythmias has evolved from
primarily pharmacological to catheter-based mapping and ablation
therapy. How has catheter-based therapy changed the practice of
pediatric cardiovascular medicine? At the Toronto Hospital for Sick
Children, 903 catheter studies were performed in 1973, and >98% were
diagnostic investigations, with the remainder being balloon atrial
septostomies and needle aspiration of pericardial fluid. During the
same year, 404 cardiac operations were performed, open and closed. In
1985, only 505 catheter procedures were performed in our institution,
while nearly 900 operations were carried out. Noninvasive imaging with
cross-sectional echocardiography permitted cardiac surgery without
angiography in many of these patients. At the conclusion of the 20th
century, 
900 operations were performed in our institution, but the
catheter numbers had dramatically increased to 925, with the
majority of these procedures now having an interventional or
therapeutic role.
Open-Heart Surgery
By 1950, some forms of surgical palliation for congenital heart disease were firmly entrenched. Pulmonary artery banding had been introduced in 1952 as a novel way to control or moderate excessive pulmonary blood flow and pulmonary artery hypertension.84 85 The introduction of cardiopulmonary bypass in the mid 1950s86 and deep hypothermia with circulatory arrest in the early 1970s provided the platform for intracardiac repair of most congenital cardiac conditions amenable to repair.87 In the early days of open-heart surgery, the older child underwent primary repair. The young infant was usually palliated with pulmonary artery banding to control excessive pulmonary blood flow and pulmonary artery hypertension, or with some form of systemic-to–pulmonary artery anastomosis to augment pulmonary blood flow. The introduction of deep hypothermia with circulatory arrest in the early 1970s provided the ability to perform primary repair of some defects even in the young infant. It was Castaneda and his colleagues at the Children’s Hospital in Boston who advocated primary repair of most conditions, including ventricular septal defect, tetralogy of Fallot, and interruption of the aortic arch with ventricular septal defect. Patients with common arterial trunk, once palliated with pulmonary artery banding, underwent primary repair in the early 1970s, with a conduit connecting the right ventricle to the pulmonary arteries.
The transition and changing outcome from palliation to
repair can be gleaned from experience with babies with complete
transposition of the great arteries. From 1950 to 1959, babies with
complete transposition of the great arteries were palliated with either
a Blalock-Hanlon atrial septectomy or one of the partial venous switch
operations pioneered by Baffes, Albert, and
others.29 36 37 88 89 90 91
Mortality for any of these procedures was substantial. Mustard
attempted an arterial switch operation with relocation of one coronary
artery in the mid 1950s, realizing the advantage of an anatomic repair,
but none of his patients
survived.92 The
contribution by Senning in 1959 of a complete venous switch had the
potential for changing the fate of the severely cyanotic baby with
complete transposition, but most surgeons in that era were unable to
reproduce the Senning operation with acceptable surgical
mortality.93 Then,
in May of 1963, William Thornton Mustard, once an orthopedic surgeon,
performed his successful inflow switch operation using autologous
pericardium, achieving a physiologic
repair.94 This
baffle operation diverted systemic venous blood through the mitral
valve and thus to the left ventricle and pulmonary arteries, while
pulmonary venous blood was baffled through the tricuspid valve to the
morphologically right ventricle and systemic circulation. This novel
approach was reproducible, and many surgeons around the globe adopted
this procedure. But the Mustard procedure could not be performed in the
neonate or young infant, and infants with complete transposition
required some form of palliation to survive to an age at which the
Mustard could be performed, usually 
1 year of age. In many centers,
the Blalock-Hanlon procedure was used until the introduction, in 1966,
by Rashkind and Miller of balloon atrial septostomy. In the early to
mid 1970s, there was a renaissance of the Senning operation, which was
performed in young babies, avoiding any palliation in many. In the next
10 to 15 years after the successful introduction of the Mustard or
Senning procedure, a "Pandora’s box" of complications were
catalogued, including mechanical complications related to the
intra-atrial baffle; sick sinus syndrome and atrial tachycardia and
flutter, reflecting damage to the sinus node and its artery; sudden
death; and systemic right ventricular
dysfunction.95 In
Toronto, 12% of babies referred to our institution with complete
transposition died before Mustard’s operation could be employed.
Because of death before Mustard’s operation and ongoing early and late
complications, especially in the group of patients with transposition
with large ventricular septal defect, there was of course interest in
achieving an anatomic repair with coronary artery relocation. Almost 2
decades after the failed attempts of Mustard to perform an anatomic
repair, this was finally accomplished in São Paulo, Brazil, by Dr
Adib
Jatene.96 97
By the late 1970s, an arterial switch operation had become the
procedure of choice for most patients with transposition of the great
arteries with ventricular septal defect. Maneuvers were introduced to
prepare the left ventricle of the patient with transposition and intact
ventricular septum for the arterial switch when the babies presented
after the first month of life. Castaneda and his colleagues in the
early 1980s introduced the concept of the neonatal arterial switch, and
this soon became the procedure of
choice.98 99 100 101
Thus, the last half of the 20th century was witness to a remarkable
change in outcomes for the baby with transposition. With the
introduction of the arterial switch operation in Toronto, only 4%
of babies now die before the arterial switch procedure, and for simple
transposition the surgical mortality is
<2%.102 What a
profound change from the observations of Liebman, Cullum, and Belloc,
who addressed the "natural" history of patients with transposition
of the great arteries in the era before balloon atrial septostomy and
Mustard repair.103
This is but one of the remarkable sagas in congenital heart disease.
Similar drama can be found in the surgical history of tetralogy of
Fallot, complex pulmonary atresia with ventricular septal defect,
interruption of the aortic arch with ventricular septal defect, the
hypoplastic left heart syndrome, and other complex anomalies amenable
only to "single" ventricle palliation, among
others.104 105 106 107 108 109 110 111 112 113 114
Finally, in the consideration of surgical alternatives, the experience
of "Baby Fae" in Loma Linda, Calif, opened the door to
cardiac replacement therapy for the hypoplastic left heart syndrome and
a wide variety of other congenital and acquired cardiac conditions in
the neonate, infant, and older
child.105 106
Today, in many centers cardiac replacement is a routinely considered
form of therapy.
Right Heart Bypass and the Fontan Experience
Glenn, Robiscek, Trusler, and Castaneda, among others, have fully documented the history of those contributions, beginning in the early 1950s with those of Carlon, Mondini, and de Marchi, which led to the successful partial right heart bypass, culminating in the successful application of the classic right-sided cavopulmonary shunt, now known around the world as the Glenn shunt.115 116 117 118 119 120 121 This experience firmly established the reality that under certain circumstances, a component of the systemic venous return could be conveyed directly into a lung without the interposition of a ventricular pumping chamber. That the classic Glenn shunt provided excellent palliation for many patients is abundantly clear from the literature, although this procedure was not without its early and late complications. Late deterioration could be explained by the development of systemic venous–to–systemic venous collaterals, which reduce effective pulmonary blood flow; systemic venous–to–pulmonary venous collaterals, a disadvantageous upper body–to–lower body ratio; or the development of pulmonary arteriovenous malformations. The complication of pulmonary arteriovenous malformations after a classic Glenn anastomosis is well described and was initially attributed to lack of pulsatile blood flow, especially to the dependent portion of the right lung. Experience with the Kawashima operation has now provided another intriguing explanation, namely, exclusion of hepatic venous flow from the pulmonary circulation. But it was the total right heart bypass as conceived and effectively carried out by Fontan and Baudet for 3 patients with tricuspid atresia that provided long-term palliation for patients with heart malformations not amenable to biventricular repair.122 123 124 The criteria for a successful Fontan operation and anatomic indications for this procedure continue to evolve, as have the surgical techniques for a total right heart bypass.123 From the original atriopulmonary connection with caval valves as used by Fontan, a number of surgical modifications introduced by De Leval in London were used to make the Fontan circulation more energy-efficient.124 Thus, in many centers, a total cavopulmonary connection, lateral tunnel, or extracardiac Fontan are now routinely used. A number of maneuvers have also been introduced to reduce Fontan mortality, including staging with a bidirectional cavopulmonary shunt with or without atrial fenestration at the time of the Fontan.125 126 127 128 129
A substantial number of complications have been attributed to a Fontan circulation.130 Some of these certainly challenge the bed-to-bench paradigm, among them, pulmonary arteriovenous malformations, protein-losing enteropathy, and plastic or mucinous bronchitis. This is not the forum to explore all these issues, but a few words about pulmonary arteriovenous malformations are germane.131 132 133 134 135 136 137 138 139 140 141 142 The etiology for the development of pulmonary arteriovenous malformations after the Fontan operation remains uncertain. Clinical practice currently suggests that exclusion of the hepatic veins and hepatic venous effluent from the pulmonary circuit may be causal to the development of pulmonary arteriovenous malformations and that inclusion of the hepatic venous blood into the pulmonary circuit may reverse their formation. This observation was apparently overlooked in one of the earliest reports of pulmonary arteriovenous shunting after Fontan’s operation. The similarities to pulmonary arteriovenous shunting in severe liver disease are interesting, and their reversal by liver transplantation is provocative.141 142 Indeed, this complication has been well documented after the Kawashima operation and reversed in most after hepatic vein inclusion,143 144 a successful maneuver also reported by others after inclusion of the hepatic veins in the pulmonary circulation after a superior cavopulmonary connection. Historically, the development of pulmonary arteriovenous malformations after the classic Glenn anastomosis has been very well documented, but in none of the substantial reviews of this complication emanating from either Yale or Toronto was hepatic venous exclusion considered to be causal.145 146 Indeed, the Toronto group speculated that maldistribution of flow to the dependent portion of the right lung and lack of pulsatile blood flow were possible causes.146 In one patient in our institution who underwent the Laks modification of the Fontan procedure with diversion of inferior caval blood to the right lung and superior caval blood to the left lung,147 pulmonary arteriovenous malformations developed only in the left lung. Duncan and his colleagues have performed a histological analysis of pulmonary arteriovenous malformations in 2 children with cyanotic congenital heart disease.139 Their study did not elucidate the role of the liver in the formation of pulmonary arteriovenous malformations. The histological correlate of pulmonary arteriovenous malformations seems to be greatly increased numbers of thin-walled vessels, but application of immunohistochemical techniques suggests that the rate of cellular proliferation is not increased. It is unclear whether the histological and immunohistochemical markers of the pulmonary arteriovenous malformations in these patients with cyanotic congenital heart disease are the same as in patients with the Weber-Osler-Rendu condition. The incidence of the development of pulmonary arteriovenous malformations in patients with cyanotic congenital heart disease is uncertain, and their ascertainment is in large part methodology-dependent, as shown by Chang and colleagues.137
Although the Fontan operation can be carried out in many centers with an operative mortality of <5%, these figures apply only to those undergoing the Fontan, not to the entire cohort. Surgical mortality thus addresses the "tip of the iceberg."130 148 149 150 151 152 Finally, the names of those inventive surgeons have become firmly entrenched in the pediatric cardiology lexicon: the Glenn shunt; the Fontan operation; the Norwood operation; the Damus-Kaye-Stansel procedure.
Outcome Analysis in Congenital Heart Disease
Surgical results address only those undergoing the operative procedure, and such results thus offer a skewed and biased prognosis or outlook. Some years ago, we demonstrated that nearly 50% of infants with tricuspid atresia either died or were excluded from Fontan’s operation.130 148 Franklin and his colleagues, reviewing the combined experience of both the Great Ormond Street Hospital for Sick Children and the Brompton Hospital several years later, had virtually the same results for patients with tricuspid atresia.149 The results for patients with right atrial isomerism are even more disappointing.150 Although a Fontan operation can be carried out in some patients with right atrial isomerism with a mortality <10%, a cohort analysis showed that only 35% of all 91 patients seen at the Toronto Hospital for Sick Children with right atrial isomerism from 1970 to 1996 were alive at 5 years. Similar results have been published by Sadiq and his colleagues, reviewing the Birmingham Children’s Hospital,153 and from the review by Gaynor and his colleagues of the Children’s Hospital of Philadelphia.154
One can use any of a number of maneuvers to enhance cohort capture or inclusion. By reviewing the fate of a large cohort, one can identify specific morphological risk factors and develop strategies to neutralize them. In this regard, the Congenital Heart Surgeons Study has provided wonderful information on outcomes in a variety of malformations, including transposition of the great arteries, hypoplastic left heart syndrome, interruption of the aortic arch, neonatal coarctation, critical pulmonary stenosis, and pulmonary atresia and intact ventricular septum. The US Natural History Study of Congenital Heart Disease Nos. 1 and 2, the Baltimore-Washington Infant Study, and the New England Regional Infant Cardiac Program are but some of the important summaries of clinical outcomes addressing both specific lesions and outcomes of infants with congenital heart disease in disparate areas of the United States.155 156 157 158 159 160
Other strategies to reduce mortality and to enhance cohort inclusion are regionalization and the development of standards for practice.161 162 163 164 There is increasing evidence that regionalization can reduce surgical mortality and thus enhance outcomes. Data from Jenkins and her colleagues showed that in-hospital mortality for surgical repair of congenital heart defects was inversely related to caseload and that when low-volume institutions carried out presumably low-risk operations, their mortality was still higher than in the larger-volume institutions. Similar results were published by Sollano and her colleagues, reviewing volume-outcome relationships for congenital heart surgery performed in New York State from 1990 to 1995. Stark, in his Glenn lecture of 1995, "How to Choose a Cardiac Surgeon," came to similar conclusions. Data from his analysis demonstrated that in England and Wales, surgical mortality in infants <1 year of age in the 2 high-volume centers was 6%, whereas in the 2 low-volume institutions, surgical mortality was 19%. Regionalization based on surgical mortality and length of stay, etc, has been carried out in Sweden, reducing from 4 centers to 2 those carrying out congenital heart surgery: from Stockholm, Lund, Uppsala, and Goteborg to Goteborg and Lund. Such changes require data. Fosburg, in his Presidential address, "Fulfilling Expectations," read at the 18th Annual Meeting of the Western Thoracic Surgical Association, stated that "you cannot manage what you cannot measure."165 He went on to say as well, "If you are not analyzing the data your program generates, the cause of your failure will remain high." One must also be cognizant of the human factors that contribute to surgical mortality and "near misses," and the specialty owes a debt of gratitude to Marc De Leval, who in such a thoughtful way has documented these issues in 2 provocative articles.166 167 In this regard, we are again cautioned by Fosburg, who states, "Hospitals have been quite successful at guarding hospital-specific information regarding their quality and efficiency. ... I believe in the public release of health outcomes information. It is a powerful motivator for change."165 Thus, disclosure of health outcomes and regionalization remain both contentious and controversial, but many of the available data are compelling. This is not to suggest, however, that some low-volume institutions cannot achieve excellent results. In regard to outcome, McCrindle, in a recent commentary, stated, "However, with increasing sophistication of surgical and medical management, mortality is becoming a less prominent issue, and the focus must shift toward morbidity, functional status, quality of life, and resource demands in both the short and long term. When mortality is equivalent with different strategies, these types of outcomes must then play into the decision-making."168
It is difficult to prove that setting standards for training
will enhance outcomes. Standards for training in pediatric cardiology
and certification was formalized by the American Board of Pediatrics
and specific training guidelines in pediatric cardiology by its
subboard in pediatric cardiology. Certification in this specialty began
in 1960, and the minimum training required was 2 years before the
examination in pediatric cardiology could be taken. The period of
minimum training was extended to 3 years in 1988. The Royal College of
Physicians and Surgeons of Canada has certified the specialty of
pediatric cardiology for >30 years and in 1996 extended its minimum
period of training from 2 to 3 years before the examination could be
taken. The Section of Cardiology of the American Academy of Pediatrics
has provided guidelines for centers providing diagnosis and
treatment.169 These
recommendations have implications for training and education as well as
for the quality of care. The Section states that a center should serve
an area with 30 000 births per year. It also makes recommendations
concerning caseloads. As an absolute minimum, a center providing
high-quality diagnostic, interventional, and electrophysiological
procedures should perform 150 catheterizations per year, with half of
these performed in neonates or infants. As an absolute minimum, they
recommend that 100 pediatric cardiac surgical procedures be performed
per year, 75 of these with extracorporeal circulation. What about
pediatric cardiac surgery? Stark takes issue with the guidelines for
certification by the American Board of Thoracic
Surgery.162 This
board requires that a candidate must operate on 20 patients with
congenital heart disease before he or she is eligible to take the
examination of the American Board of Thoracic Surgery. This is clearly
inadequate, and most candidates interested in a career in congenital
heart surgery will take an additional 1 to 2 years of fellowship in
congenital heart surgery.
Preventive Pediatric Cardiology
Over the past 50 years, data have been accumulating about our ability to prevent many types of pediatric heart disease.170 171 172 173 174 175 176 177 178 Diphtheric heart disease, which was common in the first half of the 20th century, is now a curiosity because of the success of immunization. Rheumatic fever and rheumatic heart disease in the United States also became much less common because of advances in public health. In the early 1960s, the congenital rubella syndrome was a significant contributor to congenital cardiac malformations in the population and is now virtually gone as a result of immunization. In midcentury, endocardial fibroelastosis was the most common reason for an infant without a structural heart malformation to be admitted to the hospital with heart failure or to die of an untreatable heart disease. The cases of endocardial fibroelastosis disappeared abruptly in the mid-1970s. Nearly 25 years later, when polymerase chain reaction technology became available, it could be demonstrated that some of these cases were due to prenatal mumps virus infection. The potential for prevention of additional heart disease in the population by public health interventions in youth remains. A number of biological precursors of atherosclerosis are incompletely explored. The potential exists that immunization against additional agents could be found to prevent some subclinical inflammatory cardiovascular disease in childhood that ultimately results in cardiomyopathy or vascular abnormality in adult life.
Genetics of Congenital Heart Disease
The field of pediatric cardiology has been influenced greatly by enhanced understanding of genetics over the past 50 years.179 180 181 182 183 184 185 186 187 188 189 190 Genes code for a number of the cardiovascular abnormalities that affect children. Descriptive knowledge of pediatric heart disease associated with syndromes has been of practical importance. Cardiovascular abnormalities are prevalent in many of the chromosomal defects. The specific knowledge of gene products and of genetic mechanisms of cardiovascular abnormalities in children has revolutionized many of our diagnostic approaches and is increasingly directly enhancing options for treatment.
Conclusions
The voices of some of the giants of our specialty are now stilled: Helen Taussig, Alfred Blalock, Benjamin Gasul, William Mustard, Ed Lambert, Maurice Lev, William Rashkind, Richard Rowe, John Keith, Robert Gross, Dan McNamara, Sir Russell Brock, Richard Bonham-Carter, C. Walton Lillehei, Dwight McGoon, and Alexander Nadas, to name but a few. Fortunately, their legacy survives through their many trainees who now strive on many fronts to advance this wonderful specialty. For those of us fortunate enough to have worked with them, we are truly privileged. They are the "genetics" of what we do!
References
1. Abbott ME. Atlas of Congenital Cardiac Disease. New York, NY: American Heart Association; 1939:62.
2. Taussig HB. Congenital Malformations of the Heart. Vols. I and 2. Cambridge, Mass: Harvard University Press; 1960:1049.
3.
Gross
RE, Hubbard JP. Surgical ligation of a patent ductus arteriosus: report
of first successful case. Am Med Assoc J. 1939;112:729–731.
4.
Blalock
A, Taussig HB. The surgical treatment of malformations of the heart in
which there is pulmonary stenosis or pulmonary atresia. J
Am Med Assoc. 1945;128:189–192.
5.
Crafoord
C, Nylin G. Congenital coarctation of the aorta and its surgical
treatment. J Thorac Surg. 1945;14:347–361.
6.
Brock
RC. Pulmonary valvotomy for the relief of congenital pulmonary
stenosis: report of three cases. BMJ. 1948;1:1121–1126.
7.
Blalock
A, Hanlon CR. The surgical treatment of complete transposition of the
aorta and the pulmonary artery. Surg Gynecol Obstet. 1950;90:1–15.
8.
Rudolph
AM. The changes in the circulation after birth: their importance in
congenital heart disease. Circulation. 1970;41:343.
9.
Dawes
GS, Mott JC, Widdecombe JG, et al. Changes in the lungs of the
newborn lamb. J Physiol. 1953;121:141.
10.
Adams
FH, Lind J. Physiologic changes on the cardiovascular status of
newborn infants. Pediatrics. 1957;19:431.
11.
Van
Praagh R, Ongley PA, Swan HJC. Anatomic types of single or common
ventricle in man: morphologic and geometric aspects of sixty autopsied
cases. Am J Cardiol. 1964;13:367–386.
12.
Van
Praagh R, Van Praagh S, Vlad P, et al. Anatomic types of congenital
dextrocardia: diagnostic and embryologic implications. Am
J Cardiol. 1964;13:510–531.
13.
Van
Praagh R, Van Praagh S, Vlad P, et al. Diagnosis of the anatomic types
of congenital dextrocardia. Am J Cardiol. 1965;15:234–247.
14.
Van
Praagh R. The segmental approach to diagnosis in congenital heart
disease. In: Bergsma D, ed. Birth Defects (Original Article
Series). 1972;8:4–23.
15.
Van
Praagh R. Terminology of congenital heart disease: glossary and
commentary. Circulation. 1977;56:139–143.
16.
Van
Praagh R. Diagnosis of complex congenital heart disease:
morphologic-anatomic method and terminology. Cardiovasc
Intervent Radiol. 1984;7:115–120.
17.
Van
Praagh R, Van Praagh S. Isolated ventricular inversion: a consideration
of the morphogenesis, definition and diagnosis of nontransposed and
transposed great arteries. Am J Cardiol. 1966;17:395–406.
18.
de la
Cruz MV, Anselmi G, Munoz-Castellanos L, et al. Systematization, and
embryological and anatomical study of mirror-image dextrocardias,
dextroversions, and laevoversions. Br Heart J. 1971;33:841–853.
19.
Lev M.
Pathologic diagnosis of positional variations in cardiac chambers in
congenital heart disease. Lab Invest. 1954;3:71–82.
20.
Lev M,
Liberthson RR, Golden JG, et al. The pathologic anatomy of mesocardia.
Am J Cardiol. 1971;28:428–435.
21.
Liberthson
RR, Hastreiter AR, Sinha SN, et al. Levocardia with visceral
heterotaxy-isolated levocardia: pathologic anatomy and its clinical
implications. Am Heart J. 1973;85:40–54.
22.
Macartney
FJ, Shinebourne EA, Anderson RH. Connexions, relations, discordance,
and distorsions. Br Heart J. 1976;38:323–326.
23.
Macartney
FJ, Zuberbuhler JR, Anderson RH. Morphologic considerations pertaining
to recognition of atrial isomerism: consequences for sequential chamber
localisation. Br Heart J. 1980;44:657–667.
24.
Shinebourne
EA, Macartney FJ, Anderson RH. Sequential chamber localisation: logical
approach to diagnosis in congenital heart disease. Br
Heart J. 1976;38:327–340.
25.
Stanger
P, Rudolph AM, Edwards JE. Cardiac malpositions: an overview based on
study of sixty-five necropsy specimens. Circulation. 1977;56:159–172.
26.
Anderson
RH, Becker AE, Van Mierop LHS. What should we call the "crista"?
Br Heart J. 1977;39:856–859.
27.
Abdulla
R. Terms and phrases of cardiac morphology: a call for anarchy.
Pediatr Cardiol. 2000;21:103.
28.
Anderson
RH, Macartney FJ, Shinebourne EA, et al. Paediatric Cardiology,
Vol. 1. Edinburgh, UK: Churchill Livingstone;
1987:65–82.
29.
Forssmann
W. Die Sondierung des rechten Herzen. Klin Munch Med
Wochenschr. 1929;8:2085–2089.
30.
Cournand
AF, Ranges HS. Catheterization of the right auricle in man.
Proc Soc Exp Biol Med. 1941;46:462–470.
31.
Cournand
AF. Nobel lecture, December 11, 1956. In: Nobel Lectures,
Physiology and Medicine 1942–1956. Amsterdam, Netherlands:
Elsevier; 1964:529–561.
32.
Baim
DS, Grossman W. Cardiac Catheterization, Angiography, and
Intervention. 5th ed. Baltimore, Md: Williams & Wilkins;
1996:3–7.
33.
Anabrawi
IN, Ellison RG, Ellison LT. Natural history of pulmonary hypertension
in surgically treated patent ductus arteriosus.
Circulation. 1965;31(suppl
1):61–66.
34.
Shepherd
JT, Semler HJ, Helmholz HF Jr, et al. Effects of infusion of
acetylcholine on pulmonary vascular resistance in patients with
pulmonary hypertension and congenital heart disease.
Circulation. 1959;20:381–390.
35.
Marshall
HW, Swan HJ, Burchell HB, et al. Effect of breathing oxygen on
pulmonary artery pressure and pulmonary vascular resistance in patients
with ventricular septal defect. Circulation. 1961;23:241–252.
36.
Nadas
AS. Pediatric Cardiology. Philadelphia, Pa: WB
Saunders; 1957:475.
37.
Kjellberg
SR, Mannheimer E, Rudhe U, et al. Diagnosis of Congenital Heart
Disease. 2nd ed. Chicago, Ill: Year Book Publishers Inc;
1959:866.
38.
Puyau
FA, Burko H. The tilted left anterior oblique position in the study of
congenital cardiac anomalies. Radiology. 1966;87:1069–1073.
39.
Bargeron
LM Jr, Elliott LP, Soto B, et al. Axial cineangiography in congenital
heart disease, section I: concept, technical and anatomic
considerations. Circulation. 1977;56:1075–1083.
40.
Elliott
LP, Bargeron LM, Bream PR, et al. Axial angiography in congenital heart
disease, section II: specific lesions. Circulation. 1977;56:1084–1093.
41.
Soto
B, Coghlan CH, Bargeron LM. Present status of axially angled
angiocardiography. Cardiovasc Intervent Radiol. 1984;7:156–165.
42.
Freedom
RM. Axial angiocardiography in the critically ill infant: indications
and contraindications. Cardiol Clin. 1983;1:387–411.
43.
Fellows
KE, Keane JF, Freed MD. Angled views in cineangiocardiography of
congenital heart disease. Circulation. 1977;56:485–490.
44.
Amplatz
K, Moller JH. Radiology of Congenital Heart Disease.
St Louis, Mo: Mosby Year Book;
1993:1207.
45.
Amplatz
K, Moller JH. Angiographic equipment. In: Leib DBK, ed.
Radiology of Congenital Heart Disease. St Louis, Mo:
Mosby Year Book; 1993;155–156.
46.
Kattan
KR. Angled view in pulmonary angiography. Radiology. 1970;94:79–82.
47.
Freedom
RM, Olley PM. Pulmonary arteriography in congenital heart disease.
Cathet Cardiovasc Diagn. 1976;2:309–312.
48.
Judkins
MP. Angiographic equipment: the cardiac catheterization angiography
laboratory. In: Abrams HL, ed. Coronary Arteriography: A
Practical Approach. Boston, Mass: Little, Brown & Co;
1983:1–50.
49.
Silverman
NH, Hunter S, Anderson RH, et al. Anatomical basis of cross sectional
echocardiography. Br Heart J. 1983;50:421–430.
50.
Hagler
DJ, Edwards WD, Seward JB, et al. Standardized nomenclature of the
ventricular septum and ventricular septal defects, with applications
for two-dimensional echocardiography. Mayo Clin Proc. 1985;60:741–752.
51.
Huhta
JC, Smallhorn JF, Macartney FJ. Two dimensional echocardiographic
diagnosis of situs. Br Heart J. 1982;48:97–108.
52.
Huhta
JC, Hagler DJ, Seward JB, et al. Two-dimensional echocardiographic
assessment of dextrocardia: a segmental approach. Am J
Cardiol. 1982;50:1351–1360.
53.
Sahn
DJ, Allen HD, Lange LH, et al. Cross-sectional echocardiographic
diagnosis of the sites of total pulmonary venous drainage.
Circulation. 1979;60:1317–1325.
54.
Russell
J, Justino H, Dipchand A, et al. Non-invasive imaging in congenital
heart disease. Curr Opin Cardiol. 2000;15:224–237.
55.
Olley
PM, Coceani F, Bodach E. E-type prostaglandins: a new emergency therapy
for certain cyanotic congenital heart malformations.
Circulation. 1976;53:728–731.
56.
Heymann
MA, Rudolph AM. Ductus arteriosus dilatation by prostaglandin
E1 in infants with pulmonary atresia.
Pediatrics. 1973;59:325–329.
57.
Elliott
RB, Starling MB, Neutze JM. Medical manipulation of the ductus
arteriosus. Lancet.
1975;140–142.
58.
Singh
GK, Fong LV, Salmon AP, et al. Study of low dosage prostaglandin:
usages and complications. Eur Heart J. 1994;15:377–381.
59.
Lang
P, Freed MD, Rosenthal A, et al. The use of prostaglandin
E1 in an infant with interruption of the aortic
arch. J Pediatr. 1977;91:805–807.
60.
Lang
P, Freed MD, Bierman FZ, et al. Use of prostaglandin
E1 in infants with d-transposition of the great
arteries and intact ventricular septum. Am J
Cardiol. 1979;44:76–81.
61.
Freed
MD, Heymann MA, Lewis AB, et al. Prostaglandin
E1 in infants with ductus arteriosus-dependent
congenital heart disease. Circulation. 1981;64:899–905.
62.
Friedman
WF, Fitzpatrick KM, Merritt TA, et al. The patent ductus arteriosus.
Clin Perinatol. 1978;5:411–436.
63.
Driscoll
DJ, Kugler JD, Nihill MR, et al. The use of prostaglandin
E1 in a critically ill infant with transposition
of the great arteries. J Pediatr. 1979;95:259–261.
64.
Benson
LN, Olley PM, Patel RG, et al. Role of prostaglandin
E1 infusion in the management of transposition
of the great arteries. Am J Cardiol. 1979;44:691–696.
65.
Freedom
RM, Olley PM, Coceani F, et al. The prostaglandin challenge: test to
unmask obstructed total anomalous pulmonary venous connections in
asplenia syndrome. Br Heart J. 1978;40:91–94.
66.
Woo K,
Emery J, Peabody J. Cortical hyperostosis: a complication of prolonged
prostaglandin infusion in infants awaiting cardiac transplantation.
Pediatrics. 1994;93:417–420.
67.
Ringel
RE, Brenner JI, Haney PJ, et al. Prostaglandin-induced periostitis: a
complication of long-term PGE1 infusion in an
infant with congenital heart disease. Radiology. 1982;142:657–658.
68.
Peled
N, Dagan O, Babyn P, et al. Gastric-outlet obstruction induced by
prostaglandin therapy in neonates. N Engl J
Med. 1992;327:505–510.
69.
Haworth
SG, Sauer U, Buhlmeyer K. Effect of prostaglandin
E1 on pulmonary circulation in pulmonary
atresia: a quantitative morphometric study. Br Heart
J. 1980;43:306–314.
70.
Haworth
SG, Silove ED. Pulmonary arterial structure in pulmonary atresia after
prostaglandin E2 administration. Br
Heart J. 1981;45:311–316.
71.
Cole
RB, Abman S, Aziz KU, et al. Prolonged prostaglandin
E1 infusion: histologic effects on the patent
ductus arteriosus. Pediatrics. 1981;67:816–819.
72.
Calder
AL, Kirker JA, Neutze JM, et al. Pathology of the ductus arteriosus
treated with prostaglandins: comparison with untreated cases.
Pediatr Cardiol. 1984;5:85–92.
73.
Gittenberger-De
Groot AC, Moulaert AJ, Harinck E, et al. Histopathology of the ductus
arteriosus after prostaglandin E1 administration
in ductus dependent cardiac anomalies. Br Heart
J. 1978;40:215–220.
74.
Mason
CAE, Bigras J-L, O’Blenes SB, et al. Gene transfer in utero
biologically engineers a patent ductus arteriosus in lambs by arresting
fibronectin-dependent neointimal formation. Nat Med. 1999;2:176–182.
75.
Rubio-Alvarez
V, Limon-Larson R, Soni J. Valvulotomias intracardiacas por medio de un
cateter. Arch Inst Cardiol Mexico. 1953;23:183–192.
76.
Semb
BKH, Tijonneland S, Stake G. "Balloon valvulotomy" of congenital
pulmonary valve stenosis with tricuspid valve insufficiency.
Cardiovasc Radiol. 1979;2:239–241.
77.
Kan
SJ, White RI Jr, Mitchell SE, et al. Percutaneous balloon
valvuloplasty: a new method for treating congenital pulmonary valve
stenosis. N Engl J Med. 1982;307:540–542.
78.
McCrindle
B, Kan SJ. Long-term results after balloon pulmonary valvuloplasty.
Circulation. 1991;83:1915–1922.
79.
Rashkind
WJ, Miller WW. Creation of an atrial septal defect without thoracotomy:
a palliative approach to complete transposition of the great arteries.
JAMA. 1966;196:991–992.
80.
Porstmann
W, Wierny L, Warnke H. Der Verschluss des Ductus arteriosus persistens
ohne Thorakotomie (vorläufige Mitteilung).
Thoraxchirurgie. 1967;15:199–203.
81.
Porstmann
W, Wierny L, Warnke H. Der Verschluss des Ductus arteriosus persistens
ohne Thorakotomie (zweite Mitteilung). Fortschr
Roentgenstr. 1968;109:133–148.
82.
Lock
JE, Keane JF, Fellows KE. Diagnostic and Interventional
Catheterization in Congenital Heart Disease. Boston, Mass:
Martinus Nijhoff Publishing;
1987:189.
83.
Rao PS
(ed). Transcatheter therapy in pediatric cardiology. New York, NY:
Wiley-Liss; 1993:509.
84.
Muller
WH Jr, Dammann JF Jr. The treatment of certain congenital malformations
of the heart by the creation of pulmonary stenosis to reduce pulmonary
hypertension and excessive pulmonary blood flow: a preliminary report.
Surg Gynecol Obstet. 1952;95:213–218.
85.
Nolan
SP. The origins of pulmonary artery banding. Ann Thorac
Surg. 1987;44:427–429.
86.
Lillehei
CW, Cohen M, Warden HE, et al. The direct vision intracardiac
correction of congenital anomalies by controlled cross circulation:
results in 32 patients with ventricular septal defect, tetralogy of
Fallot and atrioventricularis communis defects.
Surgery. 1955;38:11–21.
87.
Barratt-Boyes
BG. Complete correction of cardiovascular malformations in the first
two years of life using profound hypothermia. In: Barratt-Boyes BG,
Neutze JM, Harris EA, eds. Heart Disease in Infancy.
London, UK: Churchill Livingstone;
1973:25–36.
88.
Albert
HM. Surgical correction of transposition of the great vessels.
Surg Forum. 1954;5:74–76.
89.
Baffes
TG. A new method for surgical correction of transposition of the aorta
and pulmonary artery. Surg Gynecol Obstet. 1956;102:227–231.
90.
Paul
MH, Wernovsky G. Transposition of the Great Arteries. In:
Emmanouilides GC, Allen HD, Riemenschneider TA, et al. Moss and
Adams’ Heart Disease in Infants, Children, and Adolescents, Including
the Fetus, and Young Adult. Baltimore, Md: Williams & Wilkins;
1995:1154–1224.
91.
Kirklin
JW, Barratt-Boyes BG. Cardiac Surgery. 2nd ed. New
York, NY: Churchill Livingstone;
1993:1383–1467.
92.
Mustard
WT, Chute AL, Keith JD, et al. A surgical approach to transposition of
the great vessels with extracorporeal circuit.
Surgery. 1954;36:39–51.
93.
Senning
A. Surgical correction of transposition of the great vessels.
Surgery. 1959;45:966–980.
94.
Mustard
WT. Successful two-stage correction of transposition of the great
vessels. Surgery. 1964;55:469–472.
95.
Fyler
DC. D-Transposition of the great arteries. In: Fyler DC, ed.
Nadas’ Pediatric Cardiology. St Louis, Mo: Mosby-Year
Book Inc; 1992:557–575.
96.
Jatene
AD, Fontes VF, Paulista PP, et al. Anatomic correction of transposition
of the great vessels. J Thorac Cardiovasc Surg. 1976;72:364–370.
97.
Jatene
AD. Anatomic correction of transposition of the great arteries:
historical aspects. Pediatr Cardiol. 1983;4:3–8.
98.
Castaneda
AR, Jonas RA, Mayer JE Jr, et al. Cardiac Surgery of the
Neonate and Infant. Philadelphia, Pa: WB Saunders;
1994:409–438.
99.
Wernovsky
G, Mayer JE Jr, Jonas RA, et al. Factors influencing early and late
outcome of the arterial switch operation for transposition of the great
arteries. J Thorac Cardiovasc Surg. 1995;109:289–302.
100.
Kirklin
JW, Blackstone EH, Tchervenkov CI, et al. Clinical outcomes after the
arterial switch operation for transposition: patient, support,
procedural, and institutional risk factors. Congenital Heart Surgeons
Society. Circulation. 1992;86:1501–1515.
101.
Norwood
WI, Dobell AR, Freed MD, et al. Intermediate results of the arterial
switch repair: a 20-institution study. J Thorac Cardiovasc
Surg. 1988;96:854–863.
102.
Soongswang
J, Adatia, I, Newman C, et al. Mortality in potential arterial switch
candidates with transposition of the great arteries. J Am
Coll Cardiol. 1998;32:753–757.
103.
Liebman
J, Cullum L, Belloc NB. Natural history of transposition of the great
arteries: anatomy and birth and death characteristics.
Circulation. 1969;40:237–262.
104.
Jonas
RA, Quaegebeur JM, Kirklin JW, et al. Outcomes in patients with
interrupted aortic arch and ventricular septal defect: a
multiinstitutional study. J Thorac Cardiovasc
Surg. 1994;107:1099–1113.
105.
Bailey
LL, Nehlsen-Cannarella SL, Concepcion W, et al. Baboon-to-human cardiac
xenotransplantation in a neonate. JAMA. 1985;254:3321–3329.
106.
Bailey
LL, Nehlsen-Cannarella SL, Doroshow RW, et al. Cardiac
allotransplantation in newborns as therapy for hypoplastic left heart
syndrome. N Engl J Med. 1986;315:949–963.
107.
Norwood
WI, Kirklin JK, Sanders SP. Hypoplastic left heart syndrome: experience
with palliative surgery. Am J Cardiol. 1980;45:87–92.
108.
Norwood
WI, Lang P, Castaneda AR, et al. Experience with operations for
hypoplastic left heart syndrome. J Thorac Cardiovasc
Surg. 1981;82:511–519.
109.
Norwood
WI, Lang P, Hansen DD. Physiologic repair of aortic atresia:
hypoplastic left heart syndrome. N Engl J
Med. 1983;308:23–26.
110.
Norwood
WI Jr, Jacobs MJ, Murphy JD. Fontan procedure for hypoplastic left
heart syndrome. Ann Thorac Surg. 1992;54:1025–1030.
111.
Norwood
WI Jr. Hypoplastic left heart syndrome. Ann Thorac
Surg. 1991;52:688–695.
112.
Farrell
PE Jr, Chang AC, Murdison KA, et al. Outcome and assessment after the
modified Fontan procedure for hypoplastic left heart syndrome.
Circulation. 1992;85:116–122.
113.
Mayer
JE Jr. Fontan procedure for hypoplastic left heart syndrome.
Circulation. 1992;85:372–373.
114.
Puga
FJ. Modified Fontan procedure for hypoplastic left heart syndrome after
palliation with the Norwood operation. J Am Coll
Cardiol. 1991;17:1150–1151.
115.
Glenn
WWL. Circulatory bypass of the right side of the heart, IV: shunt
between superior vena cava and distal right pulmonary artery: report of
clinical application. N Engl J Med. 1958;259:117–120.
116.
Glenn
WWL, Ordway NK, Talner NS, et al. Circulatory bypass of the right side
of the heart. Circulation. 1965;31:172–189.
117.
Carlon
CA, Mondini PG, deMarchi R. Surgical treatment of some cardiovascular
disease. J Int Coll Surg. 1951;16:1–10.
118.
Robicsek
F. An epitaph for cavopulmonary anastomosis. Ann Thorac
Surg. 1982;34:208–220.
119.
Trusler
GA, Williams WG, Cohen AJ, et al. William Glenn Lecture. The
cavopulmonary shunt: evolution of a concept.Circulation. 1990;82(suppl
IV):IV-131–IV-138.
120.
Di
Carlo D, Williams WG, Freedom RM, et al. The role of cavo-pulmonary
(Glenn) anastomosis in the palliative treatment of congenital heart
disease. J Thorac Cardiovasc Surg. 1982;83:437–441.
121.
Castaneda
AR. From Glenn to Fontan: a continuing evolution.
Circulation. 1992;86(suppl
II):II-80–II-84.
122.
Fontan
F, Baudet E. Surgical repair of tricuspid atresia.
Thorax. 1971;26:240–248.
123.
Freedom
RM. The Fontan operation: indications, outcome, and survival data. In:
E. Braunwald E, series ed; Freedom RM, volume ed. Atlas of
Heart Diseases: Congenital Heart Disease. Philadelphia, Pa:
Mosby; 1997:17-1–17-10.
124.
de
Leval MR, Kilner P, Gewillig M, et al. Total cavopulmonary connection:
a logical alternative to atriopulmonary connection for complex Fontan
operations. J Thorac Cardiovasc Surg. 1988;96:682–695.
125.
Mayer
JE, Bridges ND, Lock JE, et al. Factors associated with marked
reduction in mortality for Fontan operation in patients with single
ventricle. J Thorac Cardiovasc Surg. 1992;103:444–452.
126.
Laks
H. The partial Fontan procedure: a new concept and its clinical
application. Circulation. 1990;82:1866–1867.
127.
Jonas
RA. Indications and timing for the bidirectional Glenn shunt versus the
fenestrated Fontan circulation. J Thorac Cardiovasc
Surg. 1994;108:522–524.
128.
Bridges
ND, Jonas RA, Mayer JE, et al. Bidirectional cavopulmonary anastomosis
as interim palliation for high-risk Fontan candidates.
Circulation. 1990;82(suppl
IV):IV-170–IV-176.
129.
Bridges
ND, Lock JE, Castaneda AR. Baffle fenestration with subsequent
transcatheter closure: modification of the Fontan operation for
patients at increased risk. Circulation. 1990;82:1681–1689.
130.
Freedom
RM, Hamilton R, Yoo S-J, et al. The Fontan procedure: cohort analysis
and late complications. Cardiol Young. 2000;10:307–331.
131.
Srivastava
D, Preminger TJ, Lock JE, et al. Hepatic venous blood and the
development of pulmonary arteriovenous malformations in congenital
heart disease. Circulation. 1995;92:1217–1222.
132.
Marshall
B, Duncan BW, Jonas RA. The role of angiogenesis in the development of
pulmonary arteriovenous malformations in children after cavopulmonary
anastomosis. Cardiol Young. 1997;7:370–374.
133.
Knight
WB, Mee RBB. A cure for pulmonary arteriovenous fistulas. Ann
Thorac Surg. 1995;59:999–1001.
134.
Shah
MJ, Rychik J, Fogel MA, et al. Pulmonary AV malformations after
superior cavopulmonary connection: resolution after inclusion of
hepatic veins in the pulmonary circulation. Ann Thorac
Surg. 1997;63:960–963.
135.
Kawashima
Y, Matsuki O, Yagihara T, et al. Total cavo-pulmonary shunt operation.
Semin Thorac Cardiovasc Surg. 1994;6:17–20.
136.
Lee
J, Menkis AH, Rosenberg HC. Reversal of pulmonary arteriovenous
malformation after diversion of anomalous hepatic drainage. Ann
Thorac Surg. 1998;65:848–849.
137.
Chang
R-KR, Alejos JC, Atkinson D, et al. Bubble contrast echocardiography in
detecting pulmonary arteriovenous shunting in children with
univentricular heart after cavopulmonary anastomosis. J Am
Coll Cardiol. 1999;33:2052–2058.
138.
Puga
FJ. Invited letter concerning: pulmonary arteriovenous
malformations after modified Fontan operation. J Thorac
Cardiovasc Surg. 1989;98:1144–1145.
139.
Duncan
BW, Kneebone JM, Chi EY, et al. A detailed histologic analysis of
pulmonary arteriovenous malformations in children with cyanotic
congenital heart disease. J Thorac Cardiovasc
Surg. 1999;117:931–938.
140.
Moore
JW, Kirby WC, Madden WA, et al. Development of pulmonary arteriovenous
malformations after modified Fontan operations. J Thorac
Cardiovasc Surg. 1989;98:1045–1050.
141.
Hansoti
RC, Shah NJ. Cirrhosis of liver simulating congenital cyanotic heart
disease. Circulation. 1966;33:71–77.
142.
Hansoti
RC, Sharma S. Cirrhosis of the liver simulating congenital cyanotic
heart disease. Chest. 1989;96:843–848.
143.
Laberge
J-M, Brandt ML, Lebecque P, et al. Reversal of cirrhosis-related
pulmonary shunting in two children by orthotopic liver transplantation.
Transplantation. 1992;53:1135–1138.
144.
Fewtrell
MS, Noble-Jamieson G, Revell S, et al. Intrapulmonary shunting in the
biliary atresia/polysplenia syndrome: reversal after liver
transplantation. Arch Dis Child. 1994;70:501–504.
145.
Kopf
GS, Laks H, Stansel HC, et al. Thirty-year follow-up of superior vena
cava-pulmonary artery (Glenn) shunts. J Thorac Cardiovasc
Surg. 1990;100:662–671.
146.
Cloutier
A, Ash JM, Smallhorn JF, et al. Abnormal distribution of pulmonary
blood flow after the Glenn shunt or Fontan procedure: risk of
development of arteriovenous fistulae. Circulation. 1985;72:471–479.
147.
Laks
H, Ardehali A, Grant PW, et al. Modification of the Fontan procedure:
superior vena cava to left pulmonary artery connection and inferior
vena cava to right pulmonary artery connection with adjustable atrial
septal defect. Circulation. 1995;91:2943–2947.
148.
Tam
CKH, Lightfoot NE, Finlay CD, et al. Course of tricuspid atresia in the
Fontan era. Am J Cardiol. 1989;63:589–593.
149.
Franklin
RCG, Spiegalhalter DJ, Sullivan ID, et al. Tricuspid atresia presenting
in infancy: survival and suitability for the Fontan operation.
Circulation. 1993;87:427–439.